Health · Full coverage
FDA-Cleared Home Ultrasound Device Paves Plasanmor’s Entry Into the U.S. Market
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
Unrated 2
First reported by Globes · Jun 24, 2026
What happened
Plasanmor said it signed a U.S. partnership with Ouma Health to use its FDA-cleared home ultrasound device in pregnancy care across all 50 states. The announcement sent the Israeli company’s shares up 225.4% and lifted its market value to 214.5 million shekels.
- 01Plasanmor partnered with Ouma Health to add its home ultrasound to pregnancy care.
- 02Ouma operates in all 50 U.S. states through insurers and health-system partnerships.
- 03The device received FDA clearance in November and targets obstetric care deserts.
- 04Plasanmor shares jumped 225.4% to a 214.5 million shekel market value.
- 05GE remains a nonexclusive distributor until June 2029 after a settlement.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
PulseNmore Surges 200% on U.S. Telehealth Pregnancy PartnershipJun 24, 2026Midjourney Plans Ultrasound Hardware and Spa Clinics in Surprise ExpansionJun 18, 2026Stem Cell Company Pluri Faces Delisting Threat After Market Value PlummetsJul 15, 2026Midjourney Enters Medicine With Ambitious Ultrasound Scanning PlansJun 23, 2026Israeli Biotech Antra Bio Raises $275 Million in Private Placement to Fund Operations Through 2030Jul 27, 2026Plas Fit Acquires Debt-Ridden Kibbutz Gaash Lighting Company for 8 Million ShekelsAug 3, 2026
